CLIMB BIO, INC. Operating Lease, Weighted Average Discount Rate, Percent
CLIMB BIO, INC. (CLYM) had Operating Lease, Weighted Average Discount Rate, Percent of 8.50% as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-05
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
- 2025-03-31: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
- 2024-09-30: Operating Lease, Weighted Average Discount Rate, Percent 7.50%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 8.50% 10-K · filed 2026-03-05 |
| 2025-03-31 | 8.50% 10-Q · filed 2025-05-14 |
| 2024-12-31 | 8.50% 10-K · filed 2026-03-05 |
| 2024-09-30 | 7.50% 10-Q · filed 2024-11-12 |
| 2024-06-30 | 7.50% 10-Q · filed 2024-08-14 |
| 2024-03-31 | 7.50% 10-Q · filed 2024-05-15 |
| 2023-12-31 | 7.50% 10-K · filed 2024-03-28 |
| 2023-09-30 | 7.50% 10-Q · filed 2023-11-14 |
| 2023-06-30 | 7.50% 10-Q · filed 2023-08-10 |
| 2023-03-31 | 7.50% 10-Q · filed 2023-05-11 |
| 2022-12-31 | 7.50% 10-K · filed 2023-03-06 |
| 2022-09-30 | 7.50% 10-Q · filed 2022-11-14 |
| 2022-06-30 | 7.50% 10-Q · filed 2022-08-15 |
| 2022-03-31 | 7.50% 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |